Does the LDLR rs6511720 and PCSK9 rs11591147 GG genotype indicate no inherited LDL-lowering protection?

Genetic variations in the LDLR and PCSK9 genes are critical determinants of baseline low-density lipoprotein cholesterol (LDL-C) levels and lifetime cardiovascular risk.

Clinical evidence and lipid impact

• LDLR rs6511720 (T allele): This minor regulatory variant is associated with an LDL-C reduction of approximately 0.15 to 0.26 mmol/L, translating to an estimated 11% lower risk of coronary heart disease.
• PCSK9 rs11591147 (R46L): This loss-of-function variant lowers circulating LDL-C by 0.35 to 0.55 mmol/L per allele, resulting in a substantial 20% to 50% lower risk of cardiovascular events.
• Double GG genotype: Carrying the GG genotype at both the LDLR and PCSK9 loci indicates the absolute absence of these protective alleles. Individuals with this wild-type genetic profile exhibit standard baseline population-level receptor function and lack these specific inherited cardioprotective advantages.

Mechanistic pathways of receptor regulation

• Transcriptional upregulation: The LDLR rs6511720 T allele acts as a cis-regulatory enhancer that creates a serum response element (SRE) binding site. This site recruits serum response factor (SRF), increasing hepatic LDLR promoter activity and transcription by approximately 29%, which upregulates receptor density on the hepatocyte membrane.
• Reduced receptor degradation: The PCSK9 R46L missense mutation (rs11591147) destabilizes the PCSK9 protein, making it more susceptible to proteolytic degradation. This reduction in active PCSK9 limits the lysosomal degradation of LDL receptors, allowing more receptors to recycle back to the hepatocyte surface.
• Hepatic clearance: Both genetic mechanisms ultimately lower circulating LDL-C by increasing hepatic LDL receptor density, which accelerates the clearance of LDL particles from the bloodstream.

Bottom line

• Carrying the GG genotype at both LDLR rs6511720 and PCSK9 rs11591147 confirms the absence of these specific, inherited LDL-lowering protections, leaving the individual with standard baseline receptor density and standard cardiovascular risk at these loci.